Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Enanta Pharmaceuticals Inc(ENTA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ENTA
10/09/2026: ENTA (1-star) is currently NOT-A-BUY. Pass it for now.
Enanta Pharmaceuticals is a clinical-stage biotechnology company that leverages specialized medicinal chemistry to develop treatments for viral and liver diseases. While the company has historically benefited from significant royalty income from Hepatitis C partnerships, its primary investment story now centers on the development of proprietary candidates like EDP-938 for RSV. The company possesses a solid balance sheet and a proven discovery engine, though it faces substantial execution risk as it aims to validate its internal pipeline. Key risks include intense competition from large pharmaceutical incumbents and the binary nature of clinical trial results. The stock is best suited for growth-oriented investors who can tolerate high volatility while monitoring clinical pipeline progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Enanta offers potential for significant growth if its pipeline assets receive regulatory approval. |
| Momentum investor | Weak fit | The stock often lacks sustained momentum outside of specific clinical data release windows. |
| Value investor | Weak fit | The company is in a developmental stage, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Enanta does not pay a dividend and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | The high volatility associated with clinical-stage biotech makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical results often cause massive, binary stock price movements. |
| Valuation risk | Medium / high | Valuation is highly speculative and dependent on future success probabilities. |
| Competition risk (Respiratory and Liver disease market) | High | Well-funded incumbents dominate the target therapeutic areas. |
| Business quality | Medium | The company has a proven discovery engine but lacks a commercial-stage revenue base. |
| Dividend income | Low / none | No income component is provided to shareholders. |
| Execution risk | High | Success depends entirely on the clinical and regulatory approval of new assets. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -57.09% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 352.42M USD | Price to earnings Ratio - | 1Y Target Price 21.83 |
Price to earnings Ratio - | 1Y Target Price 21.83 | ||
Volume (30-day avg) 273.7K shares | Beta 0.96 | 52 Weeks Range 10.20 - 17.15 | Updated Date 10/09/2026 |
52 Weeks Range 10.20 - 17.15 | Updated Date 10/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.42 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Royalties | Royalty payments from AbbVie for HCV products. | The company receives passive income from historical inventions, which funds current research. |
| R&D Programs | Clinical and preclinical development of viral and liver disease drugs. | The company is a 'bet' on its future scientific breakthroughs, not its current products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 44.05 | Enterprise Value 214.20M | Price to Sales(TTM) 5.4 |
Enterprise Value 214.20M | Price to Sales(TTM) 5.4 | ||
Enterprise Value to Revenue 3.28 | Enterprise Value to EBITDA 41.13 | Shares Outstanding 29.13M | Shares Floating 22.52M |
Shares Outstanding 29.13M | Shares Floating 22.52M | ||
Percent Insiders 4.67 | Percent Institutions 94.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.